FIELD: medicine.
SUBSTANCE: kit of reagents contains a solution for providing an antigen bioavailability, a blocking solution of horseradish peroxidase, a protein blocking solution, a washing solution, a solution of primary HER2 receptor antibodies, a solution of primary oestrogen receptor antibodies, a solution of primary progesterone receptor antibodies, a solution of anti-species secondary antibodies to primary antibodies, a solution of streptavidin - horseradish peroxidase, diamine benzidine, a substrate solution, a negative reference sample, three positive reference samples of breast cancer for detecting HER2, oestrogen receptors, progesterone receptors. The kit of reagents according to the invention possesses higher sensitivity and specificity. The invention may be used in medical laboratories and research establishments.
EFFECT: possibility to detect oestrogen and progesterone receptors, as well as HER2 receptors either simultaneously, or separately.
3 ex, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING HISTOLOGICAL MATERIAL OBTAINED USING VACUUM-ASSISTED BIOPSY FOR REMOVAL OF TUMOUR BED IN PATIENTS DIAGNOSED WITH BREAST CANCER HER2-POSITIVE OR THRICE-NEGATIVE SUBTYPE AFTER NEOADJUVANT SYSTEMIC THERAPY | 2023 |
|
RU2824957C1 |
METHODS AND SYSTEMS FOR IDENTIFYING AND TREATING ANTI-PROGESTIN SENSITIVE TUMOURS | 2012 |
|
RU2672874C2 |
METHOD FOR PREDICTING THE COURSE OF A PATHOLOGICAL PROCESS IN LUMINAL NON-HYPEREXPRESSION OF Her2Neu PRIMARY OPERABLE BREAST CANCER IN POSTMENOPAUSAL WOMEN | 2018 |
|
RU2694843C1 |
METHODS OF PREDICTING RESPONSE OF TRIPLE NEGATIVE MAMMARY GLAND CANCER TO THERAPY | 2011 |
|
RU2558931C2 |
METHOD FOR DETECTING THE PRESENCE OF ESTROGEN AND PROGESTERONE RECEPTORS IN TISSUE OF HER2-NEGATIVE BREAST CANCER | 2018 |
|
RU2691606C1 |
IMPROVED STRATIFICATION OF PATIENTS TO EVALUATE THERAPY SUITABILITY | 2015 |
|
RU2711452C2 |
METHOD OF TREATING BREAST CANCER WITH COMPOUND OF 4-IODINE-3-NITROBENZAMINE IN COMBINATION WITH ANTICANCER AGENTS | 2008 |
|
RU2480211C2 |
IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
METHOD FOR PREDICTION OF HORMONE-DEPENDENT BREAST CANCER | 2014 |
|
RU2559152C1 |
Authors
Dates
2014-07-27—Published
2013-05-27—Filed